ClinicalTrials.Veeva

Menu

Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF

C

Chongqing Medical University

Status

Unknown

Conditions

Lipid Disorder
Heart Failure With Preserved Ejection Fraction
Arterial Stiffness

Study type

Observational

Funder types

Other

Identifiers

NCT05095688
2020-09-19

Details and patient eligibility

About

Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.

Full description

Before the 21st century, Heart failure with preserved ejection fraction (HFpEF) was considered as a disease with simple diastolic dysfunction, but after the 21st century, HFpEF was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Other studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Adult aged >=18years old;
  2. Diagnosed with HFpEF.

Diagnostic criteria including:

  1. left ventricular ejection fraction ≥50%;
  2. with the symptoms and/or signs of heart failure;
  3. BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL;
  4. at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

Exclusion criteria

  1. LVEF less than 45% at any time;
  2. Severe liver failure; 3/Other causes of shortness of breath, such as severe pulmonary disease or severe chronic obstructive pulmonary disease;

4.Primary pulmonary hypertension; 5.Severe valvular disease of the left heart; 6.Chronically bedridden or incapacitated; 7.Age <18 years old.

Trial contacts and locations

1

Loading...

Central trial contact

Dongying Zhang, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems